Table A. SARS-CoV-2 Variants Currently or Recently Circulating in the United States and Their Susceptibility to Anti-SARS-CoV-2 Monoclonal Antibodies
Last Updated: March 6, 2023
See the Guidelines Archive for information on bamlanivimab plus etesevimab, casirivimab plus imdevimab, and variants that were previously circulating in the United States.
| WHO Label and Pango Lineage | BEB | TIX Plus CIL | SOT | |||
|---|---|---|---|---|---|---|
| In Vitro Susceptibilitya | Anticipated Clinical Activity | In Vitro Susceptibilitya | Anticipated Clinical Activity | In Vitro Susceptibilitya | Anticipated Clinical Activity | |
| Omicron BA.5 | No change | Active | Moderate reduction | Active | Marked reduction | Unlikely to be active |
| Omicron BA.4.6/BF.7 | No change | Active | Marked reduction | Unlikely to be active | Marked reduction | Unlikely to be active |
| Omicron BQ.1 | Marked reduction | Unlikely to be active | Marked reduction | Unlikely to be active | Marked reduction | Unlikely to be active |
| Omicron BQ.1.1 | Marked reduction | Unlikely to be active | Marked reduction | Unlikely to be active | Marked reduction | Unlikely to be active |
| Omicron XBB | Marked reduction | Unlikely to be active | Marked reduction | Unlikely to be active | Marked reduction | Unlikely to be active |
| Omicron XBB.1.5 | Marked reduction | Unlikely to be active | Marked reduction | Unlikely to be active | Marked reduction | Unlikely to be active |
a This information is based on the fold reduction in susceptibility reported in the FDA EUAs1-3 and in vitro neutralization studies.4-9
Key: BEB = bebtelovimab; CIL = cilgavimab; EUA = Emergency Use Authorization; FDA = Food and Drug Administration; SOT = sotrovimab; TIX = tixagevimab; WHO = World Health Organization | ||||||
References
- Food and Drug Administration. Fact sheet for healthcare providers: Emergency Use Authorization (EUA) of sotrovimab. 2022. Available at: https://www.fda.gov/media/149534/download.
- Food and Drug Administration. Fact sheet for healthcare providers: Emergency Use Authorization for Evusheld (tixagevimab co-packaged with cilgavimab). 2023. Available at: https://www.fda.gov/media/154701/download.
- Food and Drug Administration. Fact sheet for healthcare providers: Emergency Use Authorization for bebtelovimab. 2022. Available at: https://www.fda.gov/media/156152/download.
- Imai M, Ito M, Kiso M, et al. Efficacy of antiviral agents against Omicron subvariants BQ.1.1 and XBB. N Engl J Med. 2023;388(1):89-91. Available at: https://www.ncbi.nlm.nih.gov/pubmed/36476720.
- Wang Q, Iketani S, Li Z, et al. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants. Cell. 2023;186(2):279-286.e8. Available at: https://www.ncbi.nlm.nih.gov/pubmed/36580913.
- Takashita E, Yamayoshi S, Halfmann P, et al. In vitro efficacy of antiviral agents against Omicron subvariant BA.4.6. N Engl J Med. 2022;387(22):2094-2097. Available at: https://pubmed.ncbi.nlm.nih.gov/36383452/.
- Wang Q, Li Z, Ho J, et al. Resistance of SARS-CoV-2 Omicron subvariant BA.4.6. to antibody neutralisation. Lancet Infect Dis. 2022;22(12):1666-1668. Available at: https://pubmed.ncbi.nlm.nih.gov/36328002/.
- Takashita E, Yamayoshi S, Simon V, et al. Efficacy of antibodies and antiviral drugs against Omicron BA.2.12.1, BA.4, and BA.5 subvariants. N Engl J Med. 2022;387(5):468-470. Available at: https://www.ncbi.nlm.nih.gov/pubmed/35857646.
- Wang Q, Guo Y, Iketani S, et al. Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5. Nature. 2022;608(7923):603-608. Available at: https://pubmed.ncbi.nlm.nih.gov/35790190/.